Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do
2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...
596 Views
China Feihe (中国飞鹤) Post-IPO: Thoughts on Official Response to Short Seller Report
On November 21st, GMT Research issued a report on China Feihe with the title "China Feihe (6186 HK) AVOID: Fake or fabulous?" questioning China...
732 Views
China Feihe (中国飞鹤) Post-IPO: Thoughts on Short Seller Allegations
Yesterday, GMT Research issued a report on China Feihe with the title "China Feihe (6186 HK) AVOID: Fake or fabulous?" questioning China Feihe's...
628 Views
China Feihe (中国飞鹤) IPO Trading - Allocation, Peer Performance, and Upside
China Feihe, the largest domestic infant milk formula (IMF) player, raised USD 847 million at HKD 7.50 per share. In this insight, we will cover...
483 Views
China Feihe: Trading Debut, Valuation Scenario Analysis
China Feihe (6186 HK) will commence trading on Wednesday, 13 November. Feihe priced its IPO at HK$7.50 per share (at the low-end of the range). The...
471 Views